A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
July 2026
in “
Advances in Therapy
”
Research cited in this study
7 / 7 resultsresearch Patient Preferences in the Treatment of Alopecia Areata: A Review of the Literature
Patients with alopecia areata prefer effective, safe, and convenient treatments, especially topical ones.
research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment
Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
research The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata
Alopecia Areata causes emotional stress and stigma, but those with severe hair loss may adapt better.
research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Alopecia Areata: A Multifactorial Autoimmune Condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research Alopecia Areata: A Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
Similar Research
5 / 1000+ results
research Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
research 72751 Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review
research 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
research 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.